JP7258460B2 - Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２の結晶形態 - Google Patents

Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２の結晶形態 Download PDF

Info

Publication number
JP7258460B2
JP7258460B2 JP2017539596A JP2017539596A JP7258460B2 JP 7258460 B2 JP7258460 B2 JP 7258460B2 JP 2017539596 A JP2017539596 A JP 2017539596A JP 2017539596 A JP2017539596 A JP 2017539596A JP 7258460 B2 JP7258460 B2 JP 7258460B2
Authority
JP
Japan
Prior art keywords
item
compound
crystalline
chlorophenyl
isopropylaminopyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017539596A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018503649A5 (enExample
JP2018503649A (ja
Inventor
ゲイリー デクレッセンゾ，
ディーン ウェルシュ，
ペティンカ アイ． ブラホバ，
スティーブン エックス．エム． ブーリフター，
アレクサンダー アロノフ，
アリ ケシャバルツ－ショクリ，
アレクサンダー エヌ． スカンガス，
ケイシー スタヴロプロス，
ベンジャミン リトラー，
イリーナ ニコラエヴナ カディヤラ，
ロシッツァ ゲオルギエバ アラルゴバ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2018503649A publication Critical patent/JP2018503649A/ja
Publication of JP2018503649A5 publication Critical patent/JP2018503649A5/ja
Application granted granted Critical
Publication of JP7258460B2 publication Critical patent/JP7258460B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Removal Of Specific Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2017539596A 2015-01-30 2016-01-29 Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２の結晶形態 Active JP7258460B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562110449P 2015-01-30 2015-01-30
US62/110,449 2015-01-30
PCT/US2016/015829 WO2016123574A1 (en) 2015-01-30 2016-01-29 Crystalline forms of c21h22ci2n4o2

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020063198A Division JP2020100674A (ja) 2015-01-30 2020-03-31 Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２の結晶形態

Publications (3)

Publication Number Publication Date
JP2018503649A JP2018503649A (ja) 2018-02-08
JP2018503649A5 JP2018503649A5 (enExample) 2019-02-14
JP7258460B2 true JP7258460B2 (ja) 2023-04-17

Family

ID=56544441

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2017539596A Active JP7258460B2 (ja) 2015-01-30 2016-01-29 Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２の結晶形態
JP2020063198A Pending JP2020100674A (ja) 2015-01-30 2020-03-31 Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２の結晶形態
JP2021195403A Pending JP2022033866A (ja) 2015-01-30 2021-12-01 Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２の結晶形態
JP2023081553A Withdrawn JP2023096080A (ja) 2015-01-30 2023-05-17 Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２の結晶形態
JP2025050047A Pending JP2025089464A (ja) 2015-01-30 2025-03-25 Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２の結晶形態

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2020063198A Pending JP2020100674A (ja) 2015-01-30 2020-03-31 Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２の結晶形態
JP2021195403A Pending JP2022033866A (ja) 2015-01-30 2021-12-01 Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２の結晶形態
JP2023081553A Withdrawn JP2023096080A (ja) 2015-01-30 2023-05-17 Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２の結晶形態
JP2025050047A Pending JP2025089464A (ja) 2015-01-30 2025-03-25 Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２の結晶形態

Country Status (12)

Country Link
US (6) US9676746B2 (enExample)
EP (2) EP3250562B1 (enExample)
JP (5) JP7258460B2 (enExample)
CN (2) CN107406413A (enExample)
AU (5) AU2016211246B2 (enExample)
CA (2) CA3218488A1 (enExample)
ES (1) ES3009552T3 (enExample)
HK (1) HK1244274A1 (enExample)
MX (1) MX382289B (enExample)
NZ (2) NZ734041A (enExample)
SG (2) SG10202101979TA (enExample)
WO (1) WO2016123574A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015095842A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
SG10202101979TA (en) 2015-01-30 2021-04-29 Biomed Valley Discoveries Inc Crystalline forms of c21h22ci2n4o2
PT3378479T (pt) * 2016-01-27 2020-07-20 Jiangsu Hengrui Medicine Co Método para preparação de uma composição farmacêutica compreendendo um derivado de quinolina ou um seu sal
WO2021020841A1 (en) * 2019-07-29 2021-02-04 Standigm Inc. Composition for preventing or treating metabolic liver disease
US20230024584A1 (en) * 2019-11-20 2023-01-26 University Of Kentucky Research Foundation Anti-cancer compositions and methods
CN118765276A (zh) * 2022-03-08 2024-10-11 甘李药业股份有限公司 氘代化合物，及其制备方法和应用
AU2023238106A1 (en) * 2022-03-24 2024-09-26 Biomed Valley Discoveries, Inc. Deuterated analogs of pyrrole inhibitors of erk, synthesis thereof and intermediates thereto

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007537295A (ja) 2004-05-14 2007-12-20 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｅｒｋプロテインキナーゼのインヒビターとしてのピロール化合物、それらの合成、およびそれらの中間体
JP2010511689A (ja) 2006-12-06 2010-04-15 ファイザー・インク （３Ｓ）−３−［Ｎ−（Ｎ’−（２−ｔｅｒｔ−ブチルフェニル）オキサミル）アラニニル］アミノ−５−（２’，３’，５’，６’−テトラフルオロフェノキシ）−４−オキソペンタン酸の結晶形態

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599331A (en) 1984-12-24 1986-07-08 Syntex (U.S.A.) Inc. Etianic acids as antiangiogenics
JP2545522B2 (ja) 1985-10-23 1996-10-23 アルコン・ラボラトーリーズ，インコーポレイテッド テトラヒドロ脈管形成抑制ステロイド
US4771042A (en) 1985-11-25 1988-09-13 The Upjohn Company Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments
JPH04506066A (ja) 1989-06-16 1992-10-22 ジ・アップジョン・カンパニー 脈管形成を抑制するためのスラミン・タイプの化合物および脈管形成抑止ステロイド類
EP0614463B1 (en) 1991-11-22 2003-02-12 Alcon Laboratories, Inc. Angiostatic steroids
IL145757A (en) 2000-02-05 2007-12-03 Vertex Pharma History of pyrazole and pharmaceutical preparations containing them
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7304061B2 (en) 2002-04-26 2007-12-04 Vertex Pharmaceuticals Incorporated Heterocyclic inhibitors of ERK2 and uses thereof
US7582623B2 (en) 2004-05-20 2009-09-01 The Regents Of The University Of California Photoactive metal nitrosyls for blood pressure regulation and cancer therapy
NZ705372A (en) * 2012-09-18 2018-07-27 Auspex Pharmaceuticals Inc Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
US9227969B2 (en) * 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
SG10202101979TA (en) 2015-01-30 2021-04-29 Biomed Valley Discoveries Inc Crystalline forms of c21h22ci2n4o2

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007537295A (ja) 2004-05-14 2007-12-20 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｅｒｋプロテインキナーゼのインヒビターとしてのピロール化合物、それらの合成、およびそれらの中間体
JP2010511689A (ja) 2006-12-06 2010-04-15 ファイザー・インク （３Ｓ）−３−［Ｎ−（Ｎ’−（２−ｔｅｒｔ−ブチルフェニル）オキサミル）アラニニル］アミノ−５−（２’，３’，５’，６’−テトラフルオロフェノキシ）−４−オキソペンタン酸の結晶形態

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ＰｕｂＣｈｅｍ［ｏｎｌｉｎｅ］，２０１３．０７．０８，［検索日：２０１９．０８．０８］，ＰｕｂＣｈｅｍ ＣＩＤ：７１５８４４８１
小嶌隆史，医薬品開発における結晶形選択の効率化を目指して，薬剤学，２００８年９月１日，Ｖｏｌ．６８，Ｎｏ．５，ｐ．３４４－３４９
平山令明編著，有機化合物結晶作製ハンドブック－原理とノウハウ－，丸善株式会社，２００８年７月２５日，ｐ．１７－２３，３７－４０，４５－５１，５７－６５

Also Published As

Publication number Publication date
AU2016211246A1 (en) 2017-08-10
MX382289B (es) 2025-03-13
JP2025089464A (ja) 2025-06-12
AU2022228084B2 (en) 2023-11-16
AU2023254937A1 (en) 2023-11-16
JP2023096080A (ja) 2023-07-06
JP2022033866A (ja) 2022-03-02
AU2016211246B2 (en) 2020-08-27
US20220324832A1 (en) 2022-10-13
WO2016123574A1 (en) 2016-08-04
US20190127348A1 (en) 2019-05-02
US9676746B2 (en) 2017-06-13
SG10202101979TA (en) 2021-04-29
US20200339531A1 (en) 2020-10-29
EP4477222A3 (en) 2025-02-26
CA2975048C (en) 2024-01-02
AU2023254937B2 (en) 2025-08-14
JP2020100674A (ja) 2020-07-02
US10738027B2 (en) 2020-08-11
CA2975048A1 (en) 2016-08-04
ES3009552T3 (en) 2025-03-27
AU2022228084A1 (en) 2022-09-29
AU2025263912A1 (en) 2025-12-04
NZ734041A (en) 2022-02-25
AU2020257041B2 (en) 2022-06-23
CN116854662A (zh) 2023-10-10
US11390600B2 (en) 2022-07-19
EP3250562A1 (en) 2017-12-06
CA3218488A1 (en) 2016-08-04
MX2017009696A (es) 2017-10-23
NZ772411A (en) 2022-05-27
JP2018503649A (ja) 2018-02-08
US10183927B2 (en) 2019-01-22
NZ783808A (en) 2025-03-28
US20160221987A1 (en) 2016-08-04
HK1244274A1 (zh) 2018-08-03
CN107406413A (zh) 2017-11-28
US12187698B2 (en) 2025-01-07
AU2020257041C1 (en) 2022-10-27
NZ783866A (en) 2025-03-28
EP3250562B1 (en) 2024-11-27
US20250084059A1 (en) 2025-03-13
AU2020257041A1 (en) 2020-11-12
EP3250562A4 (en) 2018-07-11
EP4477222A2 (en) 2024-12-18
SG11201705924RA (en) 2017-08-30
US20170320851A1 (en) 2017-11-09

Similar Documents

Publication Publication Date Title
US12187698B2 (en) Crystalline forms of C21H22Cl2N4O2
JP7701758B2 (ja) 結晶性Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２マロン酸塩
HK40119285A (en) Crystalline 4-(5-chloro-2-isopropylaminopyridin-4-yl)-1h-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide hydrochloride salt

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190930

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190926

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200331

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201225

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20201225

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20210112

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210209

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210210

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20210430

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20210507

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220517

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220705

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20220913

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230112

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20230131

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20230301

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20230301

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230331

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230405

R150 Certificate of patent or registration of utility model

Ref document number: 7258460

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150